| 70.61 -3.25 (-4.4%) | 12-12 15:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 86.36 |
1-year : | 93.39 |
| Resists | First : | 73.93 |
Second : | 79.95 |
| Pivot price | 75.13 |
|||
| Supports | First : | 64.19 |
Second : | 53.41 |
| MAs | MA(5) : | 74.49 |
MA(20) : | 73.17 |
| MA(100) : | 77.72 |
MA(250) : | 0 | |
| MACD | MACD : | -1.2 |
Signal : | -1.5 |
| %K %D | K(14,3) : | 54.9 |
D(3) : | 65.4 |
| RSI | RSI(14): 39.4 |
|||
| 52-week | High : | 104.31 | Low : | 31.36 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ TEM ] has closed below the lower bollinger band by 1.2%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ TEM ] is to continue within current trading range. It is unclear right now based on current values. 53.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 73.93 - 74.45 | 74.45 - 74.84 |
| Low: | 68.9 - 69.58 | 69.58 - 70.11 |
| Close: | 69.67 - 70.59 | 70.59 - 71.3 |
Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company has a strategic collaborations agreement with AstraZeneca and Pathos AI, Inc. to develop therapeutic programs in oncology. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
Sun, 14 Dec 2025
Tempus AI, Inc. $TEM Shares Sold by Mission Creek Capital Partners Inc. - MarketBeat
Sun, 14 Dec 2025
Marex Group plc Makes New Investment in Tempus AI, Inc. $TEM - MarketBeat
Sun, 14 Dec 2025
Fund 1 Investments LLC Makes New Investment in Tempus AI, Inc. $TEM - MarketBeat
Fri, 12 Dec 2025
Tempus AI, Inc. Stock (TEM) Opinions on FDA Clearance and Revenue Growth - Quiver Quantitative
Thu, 11 Dec 2025
Tempus AI's Strategic Push to Expand Beyond Oncology - Yahoo Finance
Thu, 11 Dec 2025
Tempus AI's Strategic Push to Expand Beyond Oncology - Zacks Investment Research
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 173 (M) |
| Shares Float | 112 (M) |
| Held by Insiders | 39.9 (%) |
| Held by Institutions | 51.8 (%) |
| Shares Short | 22,190 (K) |
| Shares Short P.Month | 22,130 (K) |
| EPS | -0.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.85 |
| Profit Margin | -18.5 % |
| Operating Margin | -18.1 % |
| Return on Assets (ttm) | -9.1 % |
| Return on Equity (ttm) | -72.7 % |
| Qtrly Rev. Growth | 84.6 % |
| Gross Profit (p.s.) | 3.94 |
| Sales Per Share | 6.42 |
| EBITDA (p.s.) | -0.99 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -221 (M) |
| Levered Free Cash Flow | -108 (M) |
| PE Ratio | -243.49 |
| PEG Ratio | 0 |
| Price to Book value | 24.68 |
| Price to Sales | 10.99 |
| Price to Cash Flow | -55.35 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|